Alpha Cognition Inc.
Alpha Cognition (ACOG) granted 6,000 stock options to a new non-executive employee. The options have an exercise price of $8.70, vest over three years, and comply with Nasdaq Rule 5635(c)(4). The company develops treatments for neurodegenerative diseases, including Alzheimer’s and mTBI.
Opaleye Management Inc. purchased 19,050 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $8.69 ($0.17M total) on 2026-10-01.
Opaleye Management Inc. purchased 31,763 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.53 ($8.47–$8.57, $0.27M total) across 2 trades over 2026-09-24 to 2026-09-25.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ACOG (Alpha Cognition Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ACOG coverage spans insider activity, earnings and corporate actions.
In the last 30 days, ACOG insiders filed 7 SEC Form 4 transactions — 7 purchases ($1.5M) and no sales. The most active reporter was Opaleye Management Inc. with 7 filings.
The grant modestly increases share dilution and may exert slight downward pressure on the stock.
Insider purchase adds modest buying pressure.
Small insider purchase may signal confidence but size is modest relative to market cap.
The insider purchase signals confidence from a major shareholder, potentially supporting short-term price upside.
Small dilution from a modest option grant; limited immediate price impact.
AlphAI scores every news story that mentions ACOG with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Cognition Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alpha Cognition (ACOG) granted 6,000 stock options to a new non-executive employee. The options have an exercise price of $8.70, vest over three years, and comply with Nasdaq Rule 5635(c)(4). The company develops treatments for neurodegenerative diseases, including Alzheimer’s and mTBI.
1 min readOpaleye Management Inc. purchased 19,050 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $8.69 ($0.17M total) on 2026-10-01.
1 min readOpaleye Management Inc. purchased 31,763 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.53 ($8.47–$8.57, $0.27M total) across 2 trades over 2026-09-24 to 2026-09-25.
1 min readOpaleye Management Inc. purchased 123,918 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.57 ($8.40–$8.70, $1.06M total) across 4 trades over 2026-09-14 to 2026-09-16.
1 min readAlpha Cognition (ACOG) granted 20,000 stock options to a new employee, exercisable at $9.27 per share, vesting over three years. The options comply with Nasdaq Rule 5635(c)(4) and are part of the company's 2026 Inducement Grant Plan. ACOG focuses on neurodegenerative disease treatments, including ZUNVEYL for Alzheimer's and ALPHA-1062 for Alzheimer's and mTBI.
1 min readWills Robert James purchased 10,000 shares of Alpha Cognition Inc. (ACOG) at $9.62 on 2026-08-21.
1 min readB.Riley initiated coverage on Alpha Cognition (NASDAQ:ACOG) with a buy rating and $21 price target, citing strong revenue growth and high gross margins. The company reported $6M in Q2 2026 revenue, up 71% sequentially, driven by its Alzheimer's drug ZUNVEYL. Analysts highlight commercial momentum despite challenges in payer expansion.
2 min readStonegate Capital Partners updated coverage of Alpha Cognition Inc. (NASDAQ: ACOG), citing 2Q26 ZUNVEYL progress. Net product revenue rose 71% q/q to $6.0M, bottles up 37% to 8,294, and June was the strongest month since launch. Adoption broadened with 1,347 prescribers and 1,095 LTC facilities. Stonegate said FY26 R&D and SG&A guidance was lowered to $50M-$54M while keeping a 2027 profitability target.
4 min readAlpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.
6 min readAlpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.
4 min read
